Potassium-competitive acid blockers and gastroesophageal reflux disease
3
item.page.dc.date.issued
2022-07-28
item.page.dc.type
item.page.dc.identifier.issn
10079327
item.page.dc.identifier.eissn
22192840
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85135021857
item.page.dc.identifier.pmid
36161043
item.page.oaire.citation.title
World Journal of Gastroenterology
item.page.oaire.citation.volume
28
item.page.oaire.citation.issue
28
item.page.oaire.citation.startPage
3608
item.page.oaire.citation.endPage
3619
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
World Journal of Gastroenterology Vol.28 No.28 (2022) , 3608-3619
punsarn.item.page.citation
Leowattana W., Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World Journal of Gastroenterology Vol.28 No.28 (2022) , 3608-3619. 3619. doi:10.3748/wjg.v28.i28.3608 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85706
item.page.dc.title
Potassium-competitive acid blockers and gastroesophageal reflux disease
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
Proton pump inhibitors (PPIs), the most commonly used antisecretory medications in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy. However, PPI medications still leave some therapeutic demands of GERD unmet. Furthermore, up to 40%-55% of daily PPI users have chronic symptoms, due to PPI refractoriness. Potassium-competitive acid blockers (P-CABs) transcend many of the problems and limits of PPIs, delivering quick, powerful, and extended acid suppression and allowing for treatment of numerous unmet needs. Recently, it has become clear that compromised mucosal integrity plays a role in the etiology of GERD. As a result, esophageal mucosal protection has emerged as a novel and potential treatment approach. An increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs (to regular treatment), they provide a considerable extra benefit, particularly in alleviating symptoms that do not respond to PPI therapy.